Serine protease derivatives and uses in the prevention or the treatment of blood coagulation disorders

Abstract

The present invention relates to chimeric derivatives of serine protease zymogen containing the activation peptide of factor X or a fragment thereof for improving the half-life of said derivatives. Preferably, said chimeric derivatives are protein C and factor X derivatives. The invention also relates to said derivatives for the prevention or treatment of blood coagulation disorders.

The invention claimed is: 
     
       1. A chimeric thrombin-cleavable derivative of factor X comprising:
 i) activated factor X, and 
 ii) a fusion protein comprising
 a first polypeptide comprising an amino acid sequence ranging from positions 33 to 52 of SEQ ID NO:2, wherein at least one of the asparagine at positions 39 and 49 is N-glycosylated; and 
 a second polypeptide comprising an amino acid sequence ranging from positions 7 to 16 of SEQ ID NO: 4 including variants thereof wherein the glycine at position 14 of SEQ ID No. 4 is replaced by valine, phenlyalanine, or alanine and/or the valine at position 15 of SEQ. ID NO. 4 is replaced by proline. 
 
 
     
     
       2. The chimeric thrombin-cleavable derivative of factor X of  claim 1  wherein:
 i) isoleucine corresponding to a residue at position 235 of SEQ ID NO:1 is replaced by alanine, serine or leucine and/or 
 ii) valine corresponding to a residue at position 236 of SEQ ID NO:1 is replaced by phenylalanine or alanine and/or 
 iii) glycine corresponding to a residue at position 14 of SEQ ID NO:4 is replaced by valine, phenylalanine or alanine and/or 
 iv) valine corresponding to a residue at position 15 of SEQ ID NO:4 is replaced by proline. 
 
     
     
       3. The chimeric derivative of factor X of  claim 1 , wherein at least one of arginine, lysine and serine of the chimeric derivative of factor X corresponding to residues at positions 387, 391 and 419, respectively, of SEQ ID NO:1 is replaced by alanine. 
     
     
       4. A chimeric derivative of factor X of  claim 1 , wherein arginine and lysine of the chimeric derivative of factor X corresponding to residues at positions 387 and 391 of SEQ ID NO:1 are replaced by alanine. 
     
     
       5. The chimeric thrombin-cleavable derivative of factor X of  claim 1 , wherein asparagine at each of positions 39 and 49 is N-glycosylated. 
     
     
       6. The chimeric thrombin-cleavable derivative of factor X of  claim 3 , wherein each of positions 387, 391, and 419 of SEQ ID NO:1 is replaced by alanine. 
     
     
       7. The chimeric thrombin-cleavable derivative of factor X of  claim 1 , wherein
 i) asparagine at each of positions 39 and 49 is N-glycosylated and 
 ii) each of positions 387, 391, and 419 of SEQ ID NO:1 is replaced by alanine. 
 
     
     
       8. A method for the treatment of clotting pathologies of the hemorrhagic type in a subject in need thereof, comprising the step of
 administering to the subject the chimeric derivative of factor X of  claim 1 . 
 
     
     
       9. A method for the treatment of haemophilias A or B in a subject in need thereof, comprising the step of
 administering to the subject the chimeric derivative of factor X of  claim 1 . 
 
     
     
       10. A method for the treatment of bleeding induced by low molecular weight heparins (LMWH) or by an anticoagulant targeting factor Xa in a subject in need thereof, comprising the step of
 administering to the subject the chimeric derivative of factor X of  claim 1 .